There is no single case called "Defendants Mass Tort Litigation," and the supplied evidence identifies no September 2026 filing under that name. The latest documented defendant-side developments involve talc, PFAS, hernia devices, and implantable ports, plus unresolved federal PFAS reporting rules. For readers, the key takeaway is that proposed settlements have not ended these disputes. Participation conditions, claim dismissals, contested transfers, bellwether trials, and changing agency deadlines can still affect litigation strategy and individual claims.
Table of Contents
- Talc plaintiffs face a settlement choice and causation pressure
- PFAS litigation remains fragmented
- Device inventories remain large despite settlement activity
- PFAS reporting obligations are delayed, not eliminated
- What readers should check now
Talc plaintiffs face a settlement choice and causation pressure
Johnson & Johnson announced a proposed $5.5 billion resolution covering roughly 76,000 remaining ovarian-talc claims. It requires participation by firms representing at least 95% of those claims, so it was not a completed global settlement when announced. The proposal followed a July 22 order directing plaintiffs to explain why pending ovarian-talc claims should not be dismissed for insufficient specific-causation evidence.
According to Johnson & Johnson's July 27 announcement, the order came after experts were withdrawn in two bellwether cases. Specific causation means evidence connecting the defendant's product to an individual claimant's alleged injury. Claimants evaluating the proposal should ask whether their counsel plans to participate, what proof remains available, and what happens if the 95% threshold is not reached.
PFAS litigation remains fragmented
PFAS litigation covers several distinct kinds of claims rather than one consolidated dispute. These include claims involving firefighting foam, turnout gear, public water systems, property damage, and personal injury in multiple courts. In Gadsden, Alabama, a court dismissed with prejudice the claims of hundreds of water-system customers after the plaintiffs missed a deadline to amend them. A dismissal with prejudice ordinarily prevents those claims from being refiled in the same form.
According to 3M's July 21 SEC disclosure, 3M had sought judgment based on statutes of limitations. Separate exposure remains for public water providers. Eighteen Alabama systems that opted out of 3M's supplier settlement filed cases in April 2026. Seven reached the aqueous film-forming foam multidistrict litigation, or AFFF MDL, while nine conditional transfers remained contested.
Device inventories remain large despite settlement activity
Becton Dickinson reported approximately 7,090 hernia-device claims as of June 30. Although the company agreed in 2024 to settle most existing hernia litigation, no trials were scheduled, and its potential losses remained uncertain. The company also reported about 3,850 implantable-port claims in an Arizona MDL.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
An MDL coordinates similar federal cases for pretrial proceedings without automatically turning them into one class action. The first implantable-port trial in April produced a defense verdict on two claims and a mistrial on two others. Later trials were scheduled for August 18 and October 13, according to Becton Dickinson's August 6 SEC filing. A mistrial does not resolve the affected claims and may lead to another trial or settlement discussions.
PFAS reporting obligations are delayed, not eliminated
The Environmental Protection Agency postponed mandatory PFAS reporting under the Toxic Substances Control Act. Reporting had been scheduled to begin April 13, 2026, but will now start 60 days after a future rule revision.
Manufacturers and importers therefore still face possible reporting duties, while the final scope and timing remain unsettled. Businesses should preserve relevant manufacturing and import records rather than treating the postponement as a cancellation. The EPA's April 9 deadline update does not provide a new fixed start date.
What readers should check now
The significance of these developments depends on the product, court, filing deadline, and evidence tied to each claim. A corporate announcement or broad settlement figure does not establish that a particular claimant qualifies for payment.
Claimants and affected businesses can focus on four practical checks: The separate $450 million Chemours agreement resolves alleged federal and state violations involving specified PFAS facilities. It requires more than $337 million in injunctive relief, including alternative drinking water and treatment projects, but it does not resolve the wider PFAS mass-tort inventory.
- Confirm the exact court, MDL, defendant, and product listed in the case.
- Ask whether any amendment, transfer, participation, or evidence deadline applies.
- Determine whether a proposed settlement is final and whether participation conditions have been satisfied.
- Preserve medical, purchase, employment, exposure, manufacturing, and import records that may support the claim or defense.
You Might Also Like
- What Is New With Active MDL Cases Mass Tort Litigation in August 2026? Latest court filings and agency notices and Key Takeaways
- Defendants Mass Tort Litigation August 2026 Update: What Changed, Why It Matters, and What to Watch Next
- Arbitration Mass Tort Litigation September 2026 Update: What Changed, Why It Matters, and What to Watch Next